You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Manufacturing and Quality

00:00
00:00

Disclaimer: GSK does not support or promote monotherapy use of SABA. Ventolin/SABA is indicated for the treatment and/or prevention of bronchospasms8 SABAs should not be the only or main treatment in patients with asthma8. SABAs should be used appropriately with regular ICS-containing therapies as prescribed; on-demand use of SABA should not exceed 4 times daily as this may indicate deteriorating asthma control8.

Ventolin safety information1

  • Contraindications:

    Hypersensitivity to the active substance or any of the excipients.

    Non-i.v. formulations of salbutamol must not be used to arrest uncomplicated premature labour or threatened abortion.

  • Undesirable effects

    Common: Tremor, headache and Tachycardia

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

Department of Pharmacovigilance & Drug Information
Drug Safety Center
Ministry of Health, Sultanate of Oman
Phone Nos. 0096822357687 / 0096822357690
Fax: 0096822358489
Email: pharma-vigil@moh.gov.om
Website: www.moh.gov.om

دائرة التيقظ و المعلومات الدوائية
مركز سلامة الدواء
وزارة الصحة, سلطنة عمان
هاتف: 0096822357687 / 0096822357690
0096822358489 :فاكس
pharma-vigil@moh.gov.om :البريد االكتروني
www.moh.gov.om : الموقع االكتروني

Trademarks are owned by or licensed to the GSK group of companies.
©2025 GSK group of companies or its licensor. All rights reserved. 

PM-RCH-SLB-WCNT-240003 | Date of Preparation February 2025